mRNA vaccine technology
The mRNA technology has significant advantages in the R&D process and production cycles, including fast, scalable and uniform production. mRNA vaccines use antigen-encoding messenger RNA to induce humoral and cellular immunity through specific delivery systems that enable cells to take up and express the encoded antigen.It can act on intracellular and extracellular targets and express a variety of proteins without entering the nucleus and not requiring in vitro expression and purification. The development of mRNA vaccines only requires the replacement of the antigen sequence on a mature technology platform, which shows great advantages in dealing with public health emergency. CanSinoBIO’s COVID-19 mRNA vaccine and other prophylactic virus vaccine candidates are developed upon this platform.
Protein structure design and VLP assembly
We have used protein structure design technology to design pneumococcal protein antigens. In addition, we have developed novel recombinant strains to produce a new generation pertussis vaccine. We also developed a proprietary cell line to be used for viral vector production.